Analyst Recommendation: Piper Sandler analyst David Amsellem has reiterated an Overweight rating for Amgen.
Price Target: The analyst maintains a price target of $328 for the company's stock.
AMGN
$326.74+Infinity%1D
Analyst Views on AMGN
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 328.25 USD with a low forecast of 272.00 USD and a high forecast of 389.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
19 Analyst Rating
Wall Street analysts forecast AMGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AMGN is 328.25 USD with a low forecast of 272.00 USD and a high forecast of 389.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
10 Hold
1 Sell
Moderate Buy
Current: 325.310
Low
272.00
Averages
328.25
High
389.00
Current: 325.310
Low
272.00
Averages
328.25
High
389.00
Morgan Stanley
Equal Weight
downgrade
$329 -> $304
2025-12-12
New
Reason
Morgan Stanley
Price Target
$329 -> $304
2025-12-12
New
downgrade
Equal Weight
Reason
Morgan Stanley lowered the firm's price target on Amgen to $304 from $329 and keeps an Equal Weight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
HSBC
Buy
maintain
$381 -> $425
2025-12-10
Reason
HSBC
Price Target
$381 -> $425
2025-12-10
maintain
Buy
Reason
HSBC raised the firm's price target on Amgen to $425 from $381 and keeps a Buy rating on the shares as part of a 2026 outlook for the pharma group. The firm believes the sector is well positioned to outperform in 2026, "even more so if AI panic kicks in." HSBC's preferred stocks are "growth bucket ideas," but says "fallen angels and value could work as well."
Erste Group
Hold
to
Buy
upgrade
2025-12-05
Reason
Erste Group
Price Target
2025-12-05
upgrade
Hold
to
Buy
Reason
Erste Group upgraded Amgen to Buy from Hold. The firm says Amgen has a higher operating margin and return on equity than the sector average. In addition, the company's MariTide is the first obesity treatment with monthly or less frequent dosing to demonstrate safe weight loss in a Phase 2 study, the analyst tells investors in a research note. Erste sees a "favorable" valuation at current share levels.
BMO Capital
Evan Seigerman
Outperform
maintain
$335 -> $372
2025-12-03
Reason
BMO Capital
Evan Seigerman
Price Target
$335 -> $372
2025-12-03
maintain
Outperform
Reason
BMO Capital analyst Evan Seigerman raised the firm's price target on Amgen to $372 from $335 and keeps an Outperform rating on the shares. The company's MariTide Phase 2 Part 2 data has the potential to drive share strength beyond the commercial performance seen from Amgen in 202 as they represent the key remaining clinical update for Amgen in 2025 and could provide a view of MariTide's potential as a maintenance therapy, the analyst tells investors in a research note. BMO's higher price target reflects a higher probability of success for MariTide and benefits the stock has seen from an improving macro environment, the firm added.
About AMGN
Amgen Inc. is a biotechnology company. It discovers, develops, manufactures and delivers medicines for the toughest diseases. It focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve people’s lives. It operates in the human therapeutics segment. Its marketed products portfolio includes EPOGEN (epoetin alfa); Aranesp (darbepoetin alfa); Parsabiv (etelcalcetide); Neulasta (pegfilgrastim); KANJINTI (trastuzumab-anns); Otezla; BLINCYTO (blinatumomab); ACTIMMUNE (interferon gamma-1b); Neulasta (pegfilgrastim); Sensipar/Mimpara (cinacalcet); Prolia (denosumab); ENBREL; QUINSAIR (levofloxacin); Repatha (evolocumab) and others. It markets ENBREL, a tumor necrosis factor blocker, in the United States and Canada. It markets Otezla, a small molecule that inhibits phosphodiesterase 4, in many countries around the world. It markets Repatha, a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor, in many countries around the world.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
